Literature DB >> 2896127

Regulation of sterol synthesis by histamine in human mononuclear leukocytes: roles of H1- and H2-receptors.

W Krone1, D Müller-Wieland, B Behnke, H Greten.   

Abstract

The effect of histamine on sterol synthesis has been investigated in freshly isolated human mononuclear leukocytes from healthy subjects. Incubation of cells for 6 h in a medium containing lipid depleted serum led to a threefold increase in the incorporation of (14C)-acetate or tritiated water into sterols. Histamine 0.3 microM added to the incubation medium at zero time inhibited this induction by 35% with a sigmoidal log dose-effect curve. The receptors mediating this action were characterised pharmacologically by using selective H1- and H2-agonists and -antagonists. The H2-agonists impromidine and 4-methylhistamine mimicked the effect of histamine on sterol synthesis, the suppression being 42% and 31%, respectively, at a concentration of 1 microM. In contrast, the H1-agonist 2-pyridylethylamine did not affect the pathway. The H2-antagonist cimetidine (10 microM) but not the H1-antagonist mepyramine (10 microM) totally reversed the inhibition of sterol synthesis by histamine. The results provide evidence that sterol synthesis in human mononuclear leukocytes is regulated by histamine, which appears to act predominantly via H2-receptors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2896127     DOI: 10.1007/bf01061413

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  A rapid method of total lipid extraction and purification.

Authors:  E G BLIGH; W J DYER
Journal:  Can J Biochem Physiol       Date:  1959-08

2.  Histamine receptors in adipose tissue: involvement of cyclic adenosine monophosphate and the H2-receptor in the lipolytic response to histamine in isolated canine fat cells.

Authors:  V R Grund; N D Goldberg; D B Hunninghake
Journal:  J Pharmacol Exp Ther       Date:  1975-10       Impact factor: 4.030

3.  A simple and sensitive saturation assay method for the measurement of adenosine 3':5'-cyclic monophosphate.

Authors:  B L Brown; J D Albano; R P Ekins; A M Sgherzi
Journal:  Biochem J       Date:  1971-02       Impact factor: 3.857

4.  Definition and antagonism of histamine H 2 -receptors.

Authors:  J W Black; W A Duncan; C J Durant; C R Ganellin; E M Parsons
Journal:  Nature       Date:  1972-04-21       Impact factor: 49.962

5.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

6.  Impromidine (SK&F 92676) is a very potent and specific agonist for histamine H2 receptors.

Authors:  G J Durant; W A Duncan; C R Ganellin; M E Parsons; R C Blakemore; A C Rasmussen
Journal:  Nature       Date:  1978-11-23       Impact factor: 49.962

7.  Effect of catecholamines on sterol synthesis in human mononuclear cells.

Authors:  W Krone; F Hildebrandt; H Greten
Journal:  Eur J Clin Invest       Date:  1982-12       Impact factor: 4.686

8.  Hydrocortisone and human lymphocytes: increases in cyclic adenosine 3':5'-monophosphate and potentiation of adenylate cyclase-activating agents.

Authors:  G Marone; L M Lichtenstein; M Plaut
Journal:  J Pharmacol Exp Ther       Date:  1980-11       Impact factor: 4.030

9.  Specific leukocyte receptors for small endogenous hormones. Detection by cell binding to insolubilized hormone preparations.

Authors:  Y Weinstein; K L Melmon; H R Bourne; M Sela
Journal:  J Clin Invest       Date:  1973-06       Impact factor: 14.808

10.  Regulation of cholesterol synthesis by low density lipoprotein in isolated human lymphocytes. Comparison of cells from normal subjects and patients with homozygous familial hypercholesterolemia and abetalipoproteinemia.

Authors:  Y K Ho; J R Faust; D W Bilheimer; M S Brown; J L Goldstein
Journal:  J Exp Med       Date:  1977-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.